Rouas-Freiss Nathalie, Moreau Philippe, Menier Catherine, Carosella Edgardo D
Senrvice de Recherches en Hémato-Immunologie, CEA-DSV-DRM, Hôpital Saint-Louis, 1UH, 1 Avenue Claude-Vellefaux, 75475 Paris 10, France.
Semin Cancer Biol. 2003 Oct;13(5):325-36. doi: 10.1016/s1044-579x(03)00023-3.
The expression of HLA-G in cancer represents a strategy employed by tumors to avoid immune destruction. Indeed, this non-classical HLA class I molecule suppresses various immune cell functions through binding to inhibitory receptors. We here review the studies done by our group that described for the first time (i) HLA-G expression in malignancies such as melanomas, renal and breast carcinomas. (ii) the up-regulation of HLA-G gene transcription by tumor environmental factors such as cytokines and stress and by agents used in chemotherapy such as demethylating molecules, and (iii) the biological relevance of such HLA-G expression in the evasion of malignant cells from antitumor immune response.
HLA-G在癌症中的表达代表了肿瘤用于避免免疫破坏的一种策略。事实上,这种非经典的I类HLA分子通过与抑制性受体结合来抑制各种免疫细胞功能。我们在此回顾我们团队所开展的研究,这些研究首次描述了:(i)HLA-G在黑色素瘤、肾癌和乳腺癌等恶性肿瘤中的表达;(ii)细胞因子和应激等肿瘤环境因素以及去甲基化分子等化疗药物对HLA-G基因转录的上调作用;以及(iii)这种HLA-G表达在恶性细胞逃避抗肿瘤免疫反应中的生物学意义。